Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc.

OLMA

0.00

Guggenheim analyst Brad Canino maintains Olema Pharmaceuticals (NASDAQ: OLMA) with a Buy and lowers the price target from $38 to $35.